288 related articles for article (PubMed ID: 24531224)
21. Design, synthesis, biological evaluation, and docking studies of (s)-phenylalanine derivatives with a 2-cyanopyrrolidine moiety as potent dipeptidyl peptidase 4 inhibitors.
Liu Y; Wu Y; Wu H; Tang L; Wu P; Liu T; Hu Y
Chem Biol Drug Des; 2013 Aug; 82(2):140-6. PubMed ID: 23530834
[TBL] [Abstract][Full Text] [Related]
22. Discovering novel α-aminoacyl-containing proline derivatives with potent and selective inhibitory activity against dipeptidyl peptidase IV: design, synthesis, biological evaluation, and molecular modeling.
Zhang X; Wang J; Su M; Li Z; Li J; Li J; Liu H
Chem Biol Drug Des; 2012 Dec; 80(6):843-52. PubMed ID: 22726613
[TBL] [Abstract][Full Text] [Related]
23. Synthesis and Evaluation of Novel [1,2,4]Triazolo[5,1-c][1,2,4]-triazines and Pyrazolo[5,1-c][1,2,4]triazines as Potential Antidiabetic Agents.
Rusinov VL; Sapozhnikova IM; Bliznik AM; Chupakhin ON; Charushin VN; Spasov AA; Vassiliev PM; Kuznetsova VA; Rashchenko AI; Babkov DA
Arch Pharm (Weinheim); 2017 May; 350(5):. PubMed ID: 28393419
[TBL] [Abstract][Full Text] [Related]
24. Synthesis and biological evaluation of novel benzyl-substituted (S)-phenylalanine derivatives as potent dipeptidyl peptidase 4 inhibitors.
Liu Y; Si M; Tang L; Shangguan S; Wu H; Li J; Wu P; Ma X; Liu T; Hu Y
Bioorg Med Chem; 2013 Sep; 21(18):5679-87. PubMed ID: 23938053
[TBL] [Abstract][Full Text] [Related]
25. Discovery and preclinical profile of teneligliptin (3-[(2S,4S)-4-[4-(3-methyl-1-phenyl-1H-pyrazol-5-yl)piperazin-1-yl]pyrrolidin-2-ylcarbonyl]thiazolidine): a highly potent, selective, long-lasting and orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.
Yoshida T; Akahoshi F; Sakashita H; Kitajima H; Nakamura M; Sonda S; Takeuchi M; Tanaka Y; Ueda N; Sekiguchi S; Ishige T; Shima K; Nabeno M; Abe Y; Anabuki J; Soejima A; Yoshida K; Takashina Y; Ishii S; Kiuchi S; Fukuda S; Tsutsumiuchi R; Kosaka K; Murozono T; Nakamaru Y; Utsumi H; Masutomi N; Kishida H; Miyaguchi I; Hayashi Y
Bioorg Med Chem; 2012 Oct; 20(19):5705-19. PubMed ID: 22959556
[TBL] [Abstract][Full Text] [Related]
26. Identification of 3-aminomethyl-1,2-dihydro-4-phenyl-1-isoquinolones: a new class of potent, selective, and orally active non-peptide dipeptidyl peptidase IV inhibitors that form a unique interaction with Lys554.
Banno Y; Miyamoto Y; Sasaki M; Oi S; Asakawa T; Kataoka O; Takeuchi K; Suzuki N; Ikedo K; Kosaka T; Tsubotani S; Tani A; Funami M; Tawada M; Yamamoto Y; Aertgeerts K; Yano J; Maezaki H
Bioorg Med Chem; 2011 Aug; 19(16):4953-70. PubMed ID: 21764322
[TBL] [Abstract][Full Text] [Related]
27. Novel N-substituted 4-hydrazino piperidine derivative as a dipeptidyl peptidase IV inhibitor.
Gupta RC; Chhipa L; Mandhare AB; Zambad SP; Chauthaiwale V; Nadkarni SS; Dutt C
Bioorg Med Chem Lett; 2009 Sep; 19(17):5021-5. PubMed ID: 19643608
[TBL] [Abstract][Full Text] [Related]
28. Design, synthesis, biological screening, and molecular docking studies of piperazine-derived constrained inhibitors of DPP-IV for the treatment of type 2 diabetes.
Kushwaha RN; Srivastava R; Mishra A; Rawat AK; Srivastava AK; Haq W; Katti SB
Chem Biol Drug Des; 2015 Apr; 85(4):439-46. PubMed ID: 25216392
[TBL] [Abstract][Full Text] [Related]
29. Discovery of potent, selective, and orally bioavailable quinoline-based dipeptidyl peptidase IV inhibitors targeting Lys554.
Maezaki H; Banno Y; Miyamoto Y; Moritoh Y; Asakawa T; Kataoka O; Takeuchi K; Suzuki N; Ikedo K; Kosaka T; Sasaki M; Tsubotani S; Tani A; Funami M; Yamamoto Y; Tawada M; Aertgeerts K; Yano J; Oi S
Bioorg Med Chem; 2011 Aug; 19(15):4482-98. PubMed ID: 21741847
[TBL] [Abstract][Full Text] [Related]
30. DA-1229, a novel and potent DPP4 inhibitor, improves insulin resistance and delays the onset of diabetes.
Kim MK; Chae YN; Kim HD; Yang EK; Cho EJ; Choi SH; Cheong YH; Kim HS; Kim HJ; Jo YW; Son MH; Kim SH; Shin CY
Life Sci; 2012 Jan; 90(1-2):21-9. PubMed ID: 22056373
[TBL] [Abstract][Full Text] [Related]
31. Discovery of 3H-imidazo[4,5-c]quinolin-4(5H)-ones as potent and selective dipeptidyl peptidase IV (DPP-4) inhibitors: use of a carboxylate prodrug to improve bioavailability.
Ikuma Y; Hochigai H; Kimura H; Nunami N; Kobayashi T; Uchiyama K; Umezome T; Sakurai Y; Sawada N; Tadano J; Sugaru E; Ono M; Hirose Y; Nakahira H
Bioorg Med Chem; 2015 Feb; 23(4):779-90. PubMed ID: 25596166
[TBL] [Abstract][Full Text] [Related]
32. (2S,3S)-3-Amino-4-(3,3-difluoropyrrolidin-1-yl)-N,N-dimethyl-4-oxo-2-(4-[1,2,4]triazolo[1,5-a]-pyridin-6-ylphenyl)butanamide: a selective alpha-amino amide dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.
Edmondson SD; Mastracchio A; Mathvink RJ; He J; Harper B; Park YJ; Beconi M; Di Salvo J; Eiermann GJ; He H; Leiting B; Leone JF; Levorse DA; Lyons K; Patel RA; Patel SB; Petrov A; Scapin G; Shang J; Roy RS; Smith A; Wu JK; Xu S; Zhu B; Thornberry NA; Weber AE
J Med Chem; 2006 Jun; 49(12):3614-27. PubMed ID: 16759103
[TBL] [Abstract][Full Text] [Related]
33. Docking-based 3D-QSAR study for selectivity of DPP4, DPP8, and DPP9 inhibitors.
Kang NS; Ahn JH; Kim SS; Chae CH; Yoo SE
Bioorg Med Chem Lett; 2007 Jul; 17(13):3716-21. PubMed ID: 17462890
[TBL] [Abstract][Full Text] [Related]
34. Synthesis and SAR of azolopyrimidines as potent and selective dipeptidyl peptidase-4 (DPP4) inhibitors for type 2 diabetes.
Brigance RP; Meng W; Fura A; Harrity T; Wang A; Zahler R; Kirby MS; Hamann LG
Bioorg Med Chem Lett; 2010 Aug; 20(15):4395-8. PubMed ID: 20598534
[TBL] [Abstract][Full Text] [Related]
35. Synthesis, Biological Evaluation, and Molecular Docking of (R)-2-((8-(3-aminopiperidin-1-yl)-3-methyl-7-(3-methylbut-2-en-1-yl)-2,6-dioxo-2,3,6,7-tetrahydro-1H-purin-1-yl)methyl)benzonitrile as Dipeptidyl Peptidase IV Inhibitors.
Ran Y; Pei H; Shao M; Chen L
Chem Biol Drug Des; 2016 Feb; 87(2):290-5. PubMed ID: 26426933
[TBL] [Abstract][Full Text] [Related]
36. Novel DPP-4 inhibitors against diabetes.
Liu Y; Hu Y
Future Med Chem; 2014 May; 6(7):793-808. PubMed ID: 24941873
[TBL] [Abstract][Full Text] [Related]
37. Synthesis and potent inhibitory activities of carboxybenzyl-substituted 8-(3-(R)-aminopiperidin-1-yl)-7-(2-chloro/cyanobenzyl)-3-methyl-3,7-dihydro-purine-2,6-diones as dipeptidyl peptidase IV (DPP-IV) inhibitors.
Mo DW; Dong S; Sun H; Chen JS; Pang JX; Xi BM; Chen WH
Bioorg Med Chem Lett; 2015 May; 25(9):1872-5. PubMed ID: 25838146
[TBL] [Abstract][Full Text] [Related]
38. A time-resolved fluorescence probe for dipeptidyl peptidase 4 and its application in inhibitor screening.
Kawaguchi M; Okabe T; Terai T; Hanaoka K; Kojima H; Minegishi I; Nagano T
Chemistry; 2010 Dec; 16(45):13479-86. PubMed ID: 20938933
[TBL] [Abstract][Full Text] [Related]
39. The highly potent and selective dipeptidyl peptidase IV inhibitors bearing a thienopyrimidine scaffold effectively treat type 2 diabetes.
Deng J; Peng L; Zhang G; Lan X; Li C; Chen F; Zhou Y; Lin Z; Chen L; Dai R; Xu H; Yang L; Zhang X; Hu W
Eur J Med Chem; 2011 Jan; 46(1):71-6. PubMed ID: 21106276
[TBL] [Abstract][Full Text] [Related]
40. Synthesis and evaluation of structurally constrained imidazolidin derivatives as potent dipeptidyl peptidase IV inhibitors.
Wang L; Zhang B; Ji J; Li B; Yan J; Zhang W; Wu Y; Wang X
Eur J Med Chem; 2009 Aug; 44(8):3318-22. PubMed ID: 19375196
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
